Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02981446

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

Open Angle Glaucoma or Ocular Hypertension Clinical Trial

Official title:
A Phase III, Randomized, Observer-Masked, Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution 0.002% Compared With Latanoprost Ophthalmic Solution 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension- PEONY Study

Clinical Trial Summary

The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular hypertension.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02981446
Study type Interventional
Source Santen Pharmaceutical Co., Ltd.
Contact
Status Completed
Phase Phase 3
Start date January 2017
Completion date January 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05583474 - OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects Phase 3
Completed NCT01343082 - DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension Phase 3
Completed NCT02822729 - A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study Phase 3